Viridian Therapeutics, INC.\De (VRDN) — SEC Filings

Overview

Viridian Therapeutics, INC.\De (VRDN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 17, 2026: Viridian Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 17, 2026, for the period ending December 31, 2025. The company is based in Waltham, MA, and operates in the Pharmaceutical Preparations sector.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Viridian Therapeutics, INC.\De is neutral.

Filing Type Overview

Viridian Therapeutics, INC.\De (VRDN) has filed 1 ARS, 25 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 3 SC 13D/A, 1 DEFA14A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Viridian Therapeutics Files 2025 Annual Report — ARS · Apr 17, 2026 Risk: low
  Viridian Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 17, 2026, for the period ending December 31, 2025. The company is based i
• 8-K Filing — 8-K · Mar 30, 2026
• Viridian Therapeutics Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Viridian Narrows Q3 Loss to $34.6M on Soaring License Revenue — 10-Q · Nov 5, 2025 Risk: high
  Viridian Therapeutics, Inc. reported a net loss of $34.599 million for the three months ended September 30, 2025, a significant improvement from the $76.689 mil
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Oct 23, 2025 Risk: medium
  On October 21, 2025, Viridian Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits relate
• Viridian Therapeutics Files 8-K on Financials — 8-K · Oct 21, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on October 21, 2025, reporting on its results of operations and financial condition. The company, formerly known as Mir
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Oct 20, 2025 Risk: medium
  Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on October 17, 2025. The filing does not specify the other party or the nature of the a
• Viridian Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• Viridian's Q2 Net Loss Widens to $60.2M Amid R&D Surge — 10-Q · Aug 6, 2025 Risk: high
  Viridian Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The net loss for the
• Viridian Therapeutics Files 8-K: Material Agreement Announced — 8-K · Jul 30, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on July 30, 2025, that it entered into a Material Definitive Agreement. The company also disclosed information related to
• Viridian Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 24, 2025 Risk: medium
  Viridian Therapeutics, Inc. filed an 8-K on June 24, 2025, reporting events as of June 20, 2025. The filing indicates changes related to the departure of direct
• Viridian Therapeutics Files 8-K — 8-K · May 20, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly k
• Viridian Therapeutics Files 8-K on Financials — 8-K · May 6, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
• Viridian Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial
• Viridian Therapeutics Files DEF 14A for FY2024 — DEF 14A · Apr 25, 2025 Risk: low
  Viridian Therapeutics, Inc. filed a DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other
• Viridian Therapeutics Board Changes & Filings — 8-K · Apr 7, 2025 Risk: low
  Viridian Therapeutics, Inc. announced on April 2, 2025, the departure of Dr. Jonathan G. Drachman from its Board of Directors. The company also reported on comp
• Viridian Therapeutics Announces Board and Executive Changes — 8-K · Mar 10, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on March 5, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company ele
• Viridian Therapeutics Terminates Material Definitive Agreement — 8-K · Mar 4, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on March 3, 2025, the termination of a material definitive agreement. The company, formerly known as Miragen Therapeutics,
• Viridian Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025 Risk: medium
  Viridian Therapeutics, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ended December 31, 2024. The company, formerly known as Miragen Ther
• Viridian Therapeutics Files 8-K on Financials — 8-K · Feb 27, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• Viridian Therapeutics Announces Board and Officer Changes — 8-K · Jan 10, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on January 7, 2025, a change in its board of directors. Specifically, the company reported the departure of certain office
• Takeda to Acquire Viridian Therapeutics for $1 Billion — 8-K · Dec 16, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on December 16, 2024, that it has entered into a definitive agreement to be acquired by Shire B.V., a subsidiary of Takeda
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Viridian Therapeutics Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulati
• Viridian Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Miragen Therapeutics, Inc. and Signal Geneti
• SC 13G/A Filing — SC 13G/A · Oct 18, 2024
• Fairmount Funds Management Ups Stake in Viridian Therapeutics — SC 13D/A · Sep 17, 2024 Risk: medium
  Fairmount Funds Management LLC, through Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D filing regarding Viridian Therapeutics, Inc. As of Sep
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Sep 12, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on September 11, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details
• Shire to Acquire Viridian Therapeutics for $1 Billion — 8-K · Sep 10, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on September 10, 2024, that it has entered into a definitive agreement to be acquired by Shire, a Takeda company, for $24.
• Viridian Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Viridian Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Signal Genetics, Inc. and Miragen Therapeutics, I
• Viridian Therapeutics Files 8-K — 8-K · Jul 15, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on July 15, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Viridian Therapeutics Appoints New CMO, Elects Director — 8-K · Jun 20, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Ke
• Viridian Therapeutics Files Proxy Materials — DEFA14A · Jun 10, 2024 Risk: low
  Viridian Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on June 10, 2024. This filing relates to the company's proxy materials, whic
• Viridian Therapeutics Files 8-K on Financials — 8-K · May 8, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, and including financial statements and
• Viridian Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  Viridian Therapeutics, Inc.\DE (VRDN) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Viridian Therapeutics, Inc. filed a 10-Q report for the perio
• Viridian Therapeutics Announces 2024 Annual Meeting of Stockholders on June 17 — DEF 14A · Apr 26, 2024 Risk: low
  Viridian Therapeutics, Inc.\DE (VRDN) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting scheduled for June 17, 2024, at 3:00 p.m.
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Apr 16, 2024 Risk: medium
  Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on April 10, 2024. The filing does not disclose the specific nature or terms of this ag
• Fairmount Funds Boost Viridian Therapeutics Stake to 15.1% — SC 13D/A · Apr 1, 2024 Risk: medium
  Fairmount Funds Management LLC, along with its group members Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, has amended its Schedule
• Viridian Therapeutics Files 8-K on Financial Condition — 8-K · Feb 27, 2024 Risk: low
  Viridian Therapeutics, Inc. (CIK: 0001590750) filed an 8-K on February 27, 2024, reporting on its results of operations and financial condition, as well as fina
• Viridian Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: low
  Viridian Therapeutics, Inc.\DE (VRDN) filed a Annual Report (10-K) with the SEC on February 27, 2024. Viridian Therapeutics, Inc. filed its 2023 Form 10-K on Fe
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Perceptive Advisors Discloses 5.0% Passive Stake in Viridian Therapeutics — SC 13G · Jan 29, 2024
  Perceptive Advisors LLC, a New York-based investment firm, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a significant pass
• BlackRock Amends Viridian Therapeutics Stake, Signals Confidence — SC 13G/A · Jan 29, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Viridian Therapeutics, Inc.\DE as of December 31, 2023. This filing in
• Fairmount Funds Amends Viridian Therapeutics Stake (SC 13D/A) — SC 13D/A · Jan 24, 2024
  Fairmount Funds Management LLC, along with Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, filed an amended Schedule 13D on January 22

Frequently Asked Questions